Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2021 | CAR T-cells in myeloma: patients’ perspective

CAR T-cell therapy has emerged as a promising therapy for relapsed and/or refractory patients with multiple myeloma. Ananda Plate, LL.B, MSc, Myeloma Patients Europe, Brussels, Belgium, discusses the challenges associated with this therapy from a patients’ perspective. The time lag between the collection and manufacturing of CAR T-cells remains difficult for patients with progressive disease. Side-effects, access to CAR T-cells, and management of expectations are some of the other hurdles related to CAR T-cell therapy. This interview took place during the 3rd European CAR T-cell Meeting.


Myeloma Patients Europe receives funding from most of the pharmaceutical companies developing myeloma and AL amyloidosis drugs. Ananda Plate has no personal disclosures.